FREE TRIAL - NO CARD NEEDED
Pubrio gives your team the data, timing, and tools to reach the right prospects before the competition does.
Company & people search
Filter 560M+ contacts by role, industry, tech stack & more.
Sequences
Automate multi-step outreach without losing the personal touch.
Market signals
Stay ahead of every market shift. Pubrio Signals watches companies for you and delivers the right intelligence.
Start your free trial
Join 9,000+ revenue teams already using Pubrio.
No credit card · Cancel anytime · GDPR safe
Already have an account?Log in

Clarity Pharmaceuticals
Australia · Research
Medical Devices
Research
Pharmaceuticals
Biotechnology
Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the "perfect pairing" of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.
2010
Founded
Research
Industry
Australia
Location
33,204,838
Ranking
50 employees
Size

Get full access to view complete information

© 2026 Pubrio. All rights reserved.